Clinical Trial Update: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the experimental agent JSKN003 to trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• JSKN003
• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Phase 3 | Status: RECRUITING